Compare Palantir Technologies Inc (PLTR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Sana Biotechnology Inc — how do they compare? Palantir Technologies Inc trades at $169.18 (market cap $409.24B), while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Palantir Technologies Inc is far larger — about 397.3× Sana Biotechnology Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| PLTR | SANA | |
|---|---|---|
Market Cap | $409.24B | $1.03B |
Sector | Technology | Health |
52-Week High | $207.18 | $5.92 |
52-Week Low | $107.27 | $2.68 |
Enterprise Value | $400.04B | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $170.30, down 2.31% on the day, with technical indicators showing neutral signals amid strong fundamental performance. The company reported exceptional Q2 2026 results with EPS of $0.41 beating expectations by 19%, while revenue growth accelerated to 93% year-over-year. Recent news highlights the strategic Nebius partnership for sovereign AI infrastructure, positioning Palantir to address growing enterprise demand for private AI deployment solutions.
While valuation metrics remain elevated with P/E of 145.6 and P/S of 71.1, the company's 49% net margin and 38.4% ROE demonstrate strong profitability. The consensus price target of $211.38 suggests 24% upside potential, though competitive pressures and high expectations create execution risks. Investors face the tension between premium valuation and exceptional growth trajectory.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
